Here's a marijuana stock with rising large players volume that you may regret not taking a long position in. Then again, maybe not.
This company has developed the world's first prescription marijuana medicine that's now approved in many countries outside the United States.
This company's cannabis-formulated drug could generate peak annual sales of around $3 billion. At that rate, the stock could see its earnings jump a whopping 2,900% in the first year alone.